The subsequent survival analyses, which used patient data dichotomized for optimal cut-off value for adrenocortical carcinoma, acute lymphocytic leukemia, glioma, head and neck squamous cell carcinoma, kidney renal papillary cell carcinoma, kidney renal papillary cell carcinoma, sarcoma, and uveal melanoma (Figure 7A), demonstrate that the OS differences were significant for all cancers, which further confirmed that patients with high NQO1 mRNA expression had poorer outcomes except for sarcoma (Figure 7A). This evidence concerns the gene NQO1 and sarcoma.